The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
about
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathyMineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectivesAldosterone as a determinant of cardiovascular and renal dysfunctionAldosterone modulates I(f) current through gene expression in cultured neonatal rat ventricular myocytesInteraction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling.Heart failure management: the present and the future.Angiotensin II-induced protein kinase D activates the ATF/CREB family of transcription factors and promotes StAR mRNA expression.Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes.Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by ageModerate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.Advances in systolic heart failureAldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cellsModerate inappropriately high aldosterone/NaCl constellation in mice: cardiovascular effects and the role of cardiovascular epidermal growth factor receptor.Impact of intracoronary reinfusion of bone marrow-derived mononuclear progenitor cells on cardiopulmonary exercise capacity in patients with chronic postinfarction heart failure.Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.Eplerenone--a novel selective aldosterone blocker.Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?Heart failure and the brain: new perspectives.Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.Use of nonantiarrhythmic drugs for prevention of sudden cardiac death.Aldosterone receptor antagonists: biology and novel therapeutical applications.Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarctionRenal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocRole of resynchronisation therapy and implantable cardioverter defibrillators in heart failure.Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management.Inhibition of cytochromes p450: existing and new promising therapeutic targets.Cortisol stimulates proliferation and apoptosis in the late gestation fetal heart: differential effects of mineralocorticoid and glucocorticoid receptorsCardiac corticosteroid receptors mediate the enlargement of the ovine fetal heart induced by chronic increases in maternal cortisol.Nutrition and heart failure: impact of drug therapies and management strategies.Modulation of the cardiac sodium/bicarbonate cotransporter by the renin angiotensin aldosterone system: pathophysiological consequences.The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction.Aldosterone and vascular mineralocorticoid receptors: regulators of ion channels beyond the kidney.11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice.TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice.Treatment of systolic heart failure in the elderly: an evidence-based review.Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.Biomarkers: optimizing treatment guidance in heart failure.Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward.
P2860
Q24657470-8E5803C4-88E8-4EB5-A90C-A79B70BA62CCQ26741152-E0F75B00-9AFE-4CF5-9341-61582D3858A4Q28344356-90B82BA7-1FD9-4102-A87B-0E4E5B1CD380Q28580332-09932D0D-C5E7-4905-BB65-9EB88FEC8FFBQ30444722-E6B27982-38F2-4583-93EF-807E878B2010Q33605156-57D90AAF-9A6A-4B2F-976E-ACEA2EF5D326Q33765496-7F58B66B-D753-4D80-9A5C-572314FECC7CQ33787794-9BBE313A-8AAA-422E-9ECF-FFBF06E79BEDQ33871927-3C38F66E-3199-4D9B-9A44-39FB694F83A8Q34071671-3AF9DA24-7C84-4390-B894-8FC089F6E819Q34090097-1F24BD5B-C3A5-4257-BE79-AB2F1ABD0567Q34167582-8A0210C4-64F3-4FF2-8390-0DC51DC79B9FQ34392644-DA461884-194D-4916-A616-62857C3213D8Q34675520-9DAB3604-89E7-4A05-84ED-728C7C2AE42EQ34683330-A6F88ABF-ABAD-47EA-B5B7-64F3C961915EQ34778607-5EE8E1BD-27EC-4029-8185-4B8D0BB78432Q34874363-8C5F33F9-8196-46D7-9A08-4FD27B390B40Q35016271-1D85413A-A80B-47FB-9E9E-49D7A2B9AFAFQ35046024-5B8B3C04-2046-458C-8FCC-20ED0FD1304CQ35150715-9AF43964-A2E8-43A8-B9D4-A6BEFF6BF5F7Q35209701-62D8F1FA-38C5-4DC0-B5A9-5E27236AAB4BQ35605655-D3DBBB87-77F7-4B93-AB2F-5889DAFF9EEBQ35876377-EB155FBD-DCEA-4274-B697-6E40FDA1D37EQ36188016-7EE5B4F4-055D-4A2C-9526-5FA5328404EDQ36362195-209942DA-9607-463B-88D3-27AD48AD550DQ36383373-5303E131-3743-440F-9B6A-59F047A46322Q36929602-76018904-736D-4D56-9FF3-5A93E15B7FE3Q37323511-A73C75AE-63CC-4164-B173-E84C72EB8FAEQ37344274-6DC51BDA-4AAD-4894-BB28-64EA320CDCABQ37401599-3F68B83B-F03D-403A-93D3-73385D0007B7Q37488893-F76E4FDA-CA2A-456C-BDFC-77C23241AE98Q37599588-D657EDF7-6ECD-4DB3-8A7B-4D37068E5B3DQ37638481-2AEA5C5C-EDAF-450D-9CDD-32B24A47BB95Q37687153-8977D45C-F39F-46B3-93AA-269220F12E07Q37709651-6AF6B32C-BFCA-4A8B-A19B-2703CDB4C190Q37728293-53C034F6-EE89-4457-8320-9EBAD7FFC2A9Q37788881-60A6B0B1-3149-4BB7-AC52-9639BDA5967DQ37889518-4F5482BB-13D8-4AE7-B235-4ABDCFE16A1CQ37903747-9B69E832-E049-4ACE-B8FA-C25D9C871B46Q37959165-66AF001D-F125-4B13-9701-6CF514DC4AB6
P2860
The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The EPHESUS trial: eplerenone ...... e Efficacy and Survival Study.
@ast
The EPHESUS trial: eplerenone ...... e Efficacy and Survival Study.
@en
The EPHESUS trial: eplerenone ...... e Efficacy and Survival Study.
@nl
type
label
The EPHESUS trial: eplerenone ...... e Efficacy and Survival Study.
@ast
The EPHESUS trial: eplerenone ...... e Efficacy and Survival Study.
@en
The EPHESUS trial: eplerenone ...... e Efficacy and Survival Study.
@nl
prefLabel
The EPHESUS trial: eplerenone ...... e Efficacy and Survival Study.
@ast
The EPHESUS trial: eplerenone ...... e Efficacy and Survival Study.
@en
The EPHESUS trial: eplerenone ...... e Efficacy and Survival Study.
@nl
P2093
P921
P356
P1476
The EPHESUS trial: eplerenone ...... e Efficacy and Survival Study.
@en
P2093
F Martinez
G Williams
J Lopez-Sendon
P356
10.1023/A:1011119003788
P577
2001-01-01T00:00:00Z